Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Relevant molecular markers and targets.

Kathleen M Darcy1, Russel J Schilder

  • 1Translational Research Scientist, Gynecologic Oncology Group, Statistical and Data Center, Roswell Park Cancer Institute, Research Studies Center, Rm. 516, Carlton and Elm Streets, Buffalo, NY 14263, USA. darcy@gogstats.org <darcy@gogstats.org>

Gynecologic Oncology
|October 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinicopathologic and molecular predictors of survival in BRCA-deficient tubo-ovarian high-grade serous carcinoma.

Nature communications·2026
Same author

Age Comparisons of Endometrial Cancer Clinicopathology and Treatment in the United States Military Health System.

Military medicine·2026
Same author

Pathogenic germline variants among patients with ovarian cancer by self-reported ancestry: A commercial laboratory collaborative research registry study.

Gynecologic oncology·2025
Same author

Trial Enrollment and Survival Disparities Among Patients With Advanced Epithelial Ovarian Carcinoma.

JAMA network open·2025
Same author

Quantitative proteomics identifies conserved proteins and altered regulation of mucin-16 in low grade serous ovarian cancers.

Clinical proteomics·2025
Same author

Beyond <i>BRCA</i> deficiency: Clinical and molecular predictors of survival in patients with <i>BRCA</i>-deficient tubo-ovarian high-grade serous carcinoma.

medRxiv : the preprint server for health sciences·2025
Same journal

Toward precision prognosis: Predicting recurrence-free survival in high-grade serous ovarian cancer patients using multi-time point clinical and computed tomography radiomics data.

Gynecologic oncology·2026
Same journal

Adjunctive sodium-glucose cotransporter 2 (SGLT2) inhibitors with progestins and endometrial cancer risk in benign uterine diseases and hyperplasia.

Gynecologic oncology·2026
Same journal

Updated patient-reported outcomes and the effect of disease progression on health-related quality of life in the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer.

Gynecologic oncology·2026
Same journal

PRO-PLATINUM: A randomized, double-blind, placebo controlled study to investigate the efficacy of a probiotic intervention on the gut and vaginal microbiome of ovarian cancer patients undergoing treatment with platinum chemotherapy.

Gynecologic oncology·2026
Same journal

A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer.

Gynecologic oncology·2026
Same journal

Prognostic impact of time to first recurrence in low-grade serous ovarian carcinoma: A multicentric retrospective study from the French TMRG network.

Gynecologic oncology·2026
See all related articles

Ovarian cancer

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Ovarian cancer exhibits significant heterogeneity, complicating early diagnosis and treatment.
  • Molecular insights reveal numerous therapeutic targets, but a single oncogene driver is absent.
  • This necessitates combination therapies for effective ovarian cancer management.

Purpose of the Study:

  • To review molecular targets and therapeutic strategies for ovarian cancer.
  • To highlight the need for tailored combination approaches.
  • To emphasize the importance of translational research and biomarker development.

Main Methods:

  • Review of molecular mechanisms in ovarian cancer development and metastasis.
  • Discussion of various molecular targets including kinases, transferases, proteases, and deacetylases.

Related Experiment Videos

  • Emphasis on the role of targeted agents combined with cytotoxic regimens.

    • Main Results:

    • Single targeted therapies are unlikely to be effective due to ovarian cancer's heterogeneity.
    • Combination strategies targeting tumorigenesis drivers and enhancing cytotoxic activity show promise.
    • Receptor tyrosine kinases, non-receptor tyrosine kinases, and other enzymes are key targets.

    Conclusions:

    • Tailored combination therapies are crucial for ovarian cancer treatment across all stages.
    • Further research requires validated biomarkers, models, and collaborative clinical trials.
    • Advancements in drug development are essential for improving ovarian cancer diagnosis, prevention, and management.